Activity from announced rounds
Wallonie Entreprendre is the public investor identified through its Enodia announcement and Chift and Novadip coverage.
Enodia develops protein-degradation medicines. Chift connects financial software APIs, while Novadip develops regenerative cell therapies. W.IN.G and named regional funds remain distinct from the public investor.
A clinical-stage biotechnology company developing regenerative cell therapies and grafts to repair bone and other damaged tissues, including a pivotal-stage treatment for a rare pediatric bone disorder.
Develops small-molecule therapies for targeted protein degradation at the point of synthesis